| | Webinar: It’s time to expect more from your patient services hub Tuesday, November 9 | 1pm ET / 10am PT Whether you’re designing a hub services program to match the unique needs of your emerging specialty product or considering a more tailored approach to your current hub strategy, this webinar will take a look at the essential interconnectivity between data and digital services. Register Now |
WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST Weeks after a rival drug from Takeda flunked a trial, Gilead pushed back the early-stage data drop for its blood cancer therapy, picked up in last year’s $4.9 billion deal for Forty Seven. Meanwhile, the FDA granted its first approval to an eye drop to correct the farsightedness that comes with aging—a task that until now has fallen to glasses and contact lenses, affecting tens of millions. And while last year’s COVID-19 pandemic presented a once-in-a-generation challenge to many companies, several medtech CEOs met it head-on—and collected large paychecks for it. Those stories plus our top reads of the week follow below. | |
|
Featured Story | By Nick Paul Taylor Gilead’s $4.9 billion bet on Forty Seven has run into a delay. Weeks after Takeda’s rival drug flunked a pivotal trial, Gilead has pushed back the release of data from a phase 1b study designed to support accelerated approval. read more |
| |
|---|
|
| | Webinar: State of the Art Research Methods for Value-Based Pricing Wednesday, November 10, 2021 | 12pm ET / 9am PT In the healthcare industry, innovation is essential. With so many medical products developed and launched daily, pharmaceutical, healthcare services, biotechnology, medical device, diagnostic, and life science companies should clearly understand if products fit the needs of the market. To answer this, you must identify what your customers perceive as valuable. Register now. |
Top Stories Of The Week By Angus Liu For patients with presbyopia, or age-related blurry near vision, wearing glasses or contact lens has long been the mainstay correction method. Thanks to a new FDA approval, they now have an eye drop option. read more By Conor Hale,Andrea Park The COVID-19 pandemic presented a once-in-a-generation challenge for the medtech industry, and many of the CEOs on this list met it head-on. read more By Annalee Armstrong We finally know who Moderna has been courting behind the scenes to make the big jump into gene editing. The famed biotech has signed a research partnership with CRISPR gene editing company Metagenomi. read more By Angus Liu About two decades ago, Novartis transformed leukemia treatment with the introduction of Gleevec. Now, the Swiss pharma has ushered a third-generation therapy targeted against the blood cancer across the regulatory finish line. read more By Angus Liu When the FDA dropped the bombshell that it would add more safety warnings and restrict the use of JAK inhibitors, industry watchers began weighing the impact on a key player: AbbVie’s Rinvoq. But right now, even AbbVie’s CEO isn’t sure how much damage the update will do. read more By Conor Hale The race for the next major advancement in diabetes tracking technology continues to heat up, with Biolinq securing a hefty $100 million in investor support to kick-start the development of its wearable, noninvasive glucose sensor patch. read more By Nick Paul Taylor The founder of a biotech bought by Gilead has birthed another startup. Dania Therapeutics begins life with a discovery program based on Kristian Helin’s work and plans to advance small-molecule inhibitors of new oncology targets. read more By Joseph Keenan Merck has signed on to help SaudiVax of Saudi Arabia design and construct a multimodality biologics manufacturing facility as part of the country’s efforts to provide a more localized production infrastructure for the Middle East, Northern Africa region. read more By Angus Liu AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run. read more By Arlene Weintraub MIT scientists discovered a subset of T cells that become dysfunctional because of changes in gene expression that occur while they’re being activated in the lymph nodes. They reactivated the T cells in mouse models of non-small cell lung cancer with two cytokines, offering insights into improving responses to immuno-oncology drugs in people, they said. read more Resources Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Blue Matter Consulting Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: TransPerfect Life Sciences Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. | 